<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Systemic Hypertension</journal-id><journal-title-group><journal-title xml:lang="en">Systemic Hypertension</journal-title><trans-title-group xml:lang="ru"><trans-title>Системные гипертензии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-082X</issn><issn publication-format="electronic">2542-2189</issn><publisher><publisher-name xml:lang="en">Intermedservice Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33545</article-id><article-id pub-id-type="doi">10.26442/2075082X.2019.2.000030</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Acute heart failure and microRNA</article-title><trans-title-group xml:lang="ru"><trans-title>Острая сердечная недостаточность и микроРНК</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nasonova</surname><given-names>Svetlana N</given-names></name><name xml:lang="ru"><surname>Насонова</surname><given-names>Светлана Николаевна</given-names></name></name-alternatives><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ИКК им. А.Л. Мясникова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mindzaev</surname><given-names>Dzambolat R</given-names></name><name xml:lang="ru"><surname>Миндзаев</surname><given-names>Дзамболат Роланович</given-names></name></name-alternatives><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирант отд. заболеваний миокарда и сердечной недостаточности ИКК им. А.Л. Мясникова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zhirov</surname><given-names>Igor V</given-names></name><name xml:lang="ru"><surname>Жиров</surname><given-names>Игорь Витальевич</given-names></name></name-alternatives><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ИКК им. А.Л. Мясникова; проф. каф. кардиологии</p></bio><email>izhirov@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tereshchenko</surname><given-names>Sergei N</given-names></name><name xml:lang="ru"><surname>Терещенко</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., первый зам. ген. дир., зам. ген. дир. по научной работе, рук. отд. заболеваний миокарда и сердечной недостаточности</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Cardiology</institution></aff><aff><institution xml:lang="ru">ФГБУ «НМИЦ кардиологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО РМАНПО</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2019</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en">VOL 16, NO2 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 16, №2 (2019)</issue-title><fpage>42</fpage><lpage>46</lpage><history><date date-type="received" iso-8601-date="2020-04-16"><day>16</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/2075-082X/article/view/33545">https://journals.eco-vector.com/2075-082X/article/view/33545</self-uri><abstract xml:lang="en"><p>MicroRNA is a class of non-coding, single-stranded RNA 19-24 nucleotides in length, the main function of which is to inhibit the expression of protein-coding genes at the post-transcriptional level. It is known that microRNAs are an important pathogenetic link in the development of many diseases, including cardiovascular ones. Different levels of expression of these molecules in different pathologies make microRNAs potential diagnostic and prognostic biomarkers. Numerous studies confirm the fact of changes in the profile of microRNA expression in heart failure (HF). However, it is worth noting that the vast majority of these studies included patients with stable chronic HF, while the connection of these molecules with acute HF has received far less attention. Acute HF is the main cause of hospitalization for older patients. However, taking into account the low prognostic ability of existing biological markers of HF, the search for a new biological marker with a high prognostic significance is an important task of modern medicine. The article provides a brief overview of the research on the evaluation of diagnostic and prognostic abilities of a new potential of the biomarker in acute HF.</p></abstract><trans-abstract xml:lang="ru"><p>МикроРНК - класс некодирующих, одноцепочных РНК длиной 19-24 нуклеотидов, основной функцией которых является ингибирование экспрессии белок-кодирующих генов на посттранскрипционном уровне. Известно, что микроРНК являются важным патогенетическим звеном в развитии множества заболеваний, в том числе и сердечно-сосудистых. Разный уровень экспрессии данных молекул при различных патологиях позволяет рассматривать микроРНК в качестве потенциального диагностического и прогностического биомаркера. Многочисленные исследования подтверждают факт изменения профиля экспрессии микроРНК при сердечной недостаточности (СН). Однако подавляющее большинство этих исследований включали в себя пациентов со стабильной хронической СН, в то время как связи этих молекул с острой СН уделялось гораздо меньшее внимание. Острая СН является основной причиной госпитализации пациентов старшей возрастной группы, однако, с учетом низкой прогностической способности имеющихся биологических маркеров СН, поиск нового биологического маркера с высокой прогностической значимостью является важной задачей современной медицины. Данная статья содержит краткий обзор исследований, посвященных оценке диагностических и прогностических способностей нового потенциального биомаркера при острой СН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acute heart failure</kwd><kwd>microRNA</kwd><kwd>a biomarker</kwd><kwd>diagnostics</kwd><kwd>prognosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>острая сердечная недостаточность</kwd><kwd>микроРНК</kwd><kwd>биомаркер</kwd><kwd>диагностика</kwd><kwd>прогноз</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Weber J.A, Baxter D.H, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Romakina V.V, Zhirov I.V, Nasonova S.N et al. Micro RNA as Biomarkers of Cardiovascular Diseases: Large Opportunities of Small Molecules. Cardiology 2018; 58 (1): 66-71. DOI: 10.18087/cardio.2018.1.10083</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Givertz M.M, Teerlink J.R, Albert N.M et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Maisel A.S, Richards A.M, Pascual-Figal D, Mueller C. Serial ST2 testing in hospitalized patients with acute heart failure. Am J Cardiol 2015; 115: 32B-37B.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pascual-Figal D.A, Caballero L, Sanchez-Mas J, Lax A. Prognostic markers for acute heart failure. Expert Opin Med Diagn 2013; 7: 379-92.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ouwerkerk W, Voors A.A, Zwinderman A.H. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429-36.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Rahimi K, Bennett D, Conrad N et al. Risk prediction in patients with heart failure. JACC Heart Fail 2014; 2: 440-6.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bayés-Genis A, Lanfear D.E, de Ronde M.W.J et al. Pinto: Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patient. Eur J Heart Fail 2018; 20: 67-75.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kochetov A.G, Lyang O.V, Gimadiev R.R et al. Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies. Lab Serv 2016; 1: 26-32. DOI: 10.17116/labs20165126-32</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Masson S, Batkai S, Beermann J et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Failure 2018; 20: 78-85.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tijsen A.J, Creemers E.E, Moerland P.D et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ellis K.L, Cameron V.A, Troughton R.W et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-47.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Seronde M.F, Vausort M, Gayat E.J et al. GREAT Network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10: e0142237.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bruno N, ter Maaten J.M, Ovchinnikova E.S et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol 2016; 203: 564-9.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ovchinnikova E.S, Schmitter D, Vegter E.L et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18: 414-23.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Vegter E.L, Schmitter D, Hagemeijer Y et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231-9.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Vegter E.L, van der Meer P, Voors A.A. Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail 2017; 19 (8): 1077-8.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Melman Y.F, Shah R, Danielson K et al. Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation 2015; 131: 2202-16.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Xiao J, Gao R, Bei Y et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017; 41: 865-74.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Van Boven N, Kardys I, van Vark L.C et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2018; 20: 89-96.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Жиров И.В., Кочетов А.Г., Засеева А.В. и др. МикроРНК в диагностике хронической сердечной недостаточности: состояние проблемы и результаты пилотного исследования. Системные гипертензии. 2016; 13 (1): 39-46.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Goren Y, Kushnir M, Zafrir B et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-54</mixed-citation></ref></ref-list></back></article>
